Patient-Derived Xenografts (PDX) in Oncology: Advancing Personalized Cancer Research and Precision Drug Development

 

Patient-Derived Xenografts (PDX) in Oncology: Advancing Personalized Cancer Research and Precision Drug Development

Cancer is not a single disease. Every tumor can contain a complex mixture of genetic alterations, cellular populations, molecular characteristics, and treatment-response patterns. This biological complexity has created a major challenge for researchers and clinicians seeking to develop more effective and personalized cancer treatments.

Traditional laboratory models have played an important role in understanding cancer biology and evaluating potential therapies. However, many conventional models do not fully reproduce the biological complexity of human tumors. This has encouraged researchers to explore more clinically relevant experimental systems that can preserve important characteristics of patient tumors.

Patient-Derived Xenografts (PDX) have emerged as an important model in translational oncology and precision cancer research. In a PDX model, tumor tissue obtained from a patient is implanted into an immunodeficient animal, commonly a mouse, where the tumor can grow and be studied under controlled experimental conditions.

Unlike many traditional cancer cell-line models, PDX models can preserve several features of the original patient tumor, including aspects of tumor architecture, heterogeneity, molecular characteristics, and therapeutic response. This makes them valuable tools for studying cancer progression, evaluating candidate therapies, investigating drug resistance, and supporting personalized treatment research.

As precision oncology continues to evolve, PDX models are increasingly being integrated with genomic profiling, transcriptomics, proteomics, drug screening, biomarker discovery, and other advanced technologies. These approaches may help researchers better understand why certain tumors respond to particular therapies while others develop resistance.

What Are Patient-Derived Xenografts?

Patient-Derived Xenografts are experimental cancer models created by transferring tumor tissue obtained from a patient into an immunodeficient animal.

The basic process involves collecting a tumor sample, processing the tissue when necessary, and implanting it into an immunocompromised or immunodeficient mouse. Because the animal has a reduced immune response, the human tumor can establish and grow within the experimental environment.

Once the tumor becomes established, researchers can expand the model and use it for a variety of investigations. These may include testing anticancer drugs, studying tumor biology, examining treatment resistance, and identifying potential biomarkers.

PDX models can be generated from different types of cancer, including breast cancer, colorectal cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, melanoma, and several other malignancies.

The ability to establish models from individual patient tumors is particularly important for precision oncology because it provides an opportunity to study cancer using biologically relevant tumor material rather than relying exclusively on long-established laboratory cell lines.

Why Are PDX Models Important in Oncology?

One of the major challenges in cancer research is accurately predicting how a human tumor will behave in response to treatment.

A drug that produces promising results in a simplified laboratory model may not demonstrate the same effectiveness in patients. Tumor heterogeneity, interactions between different cell populations, genetic alterations, and mechanisms of resistance can all influence therapeutic outcomes.

PDX models can provide an intermediate research platform between laboratory experiments and clinical studies.

They allow researchers to investigate patient-derived tumors in a living biological environment while maintaining experimental control.

This can be particularly valuable for:

• Drug development
• Preclinical therapy testing
• Biomarker discovery
• Investigation of treatment resistance
• Tumor biology research
• Precision oncology
• Combination therapy evaluation
• Translational cancer research
• Personalized treatment research

By maintaining characteristics of patient tumors, PDX models can help researchers investigate cancer biology in a more clinically relevant context.

How Are PDX Models Created?

The development of a PDX model generally begins with the collection of tumor tissue from a patient.

The sample may come from a surgical specimen, biopsy, metastatic lesion, or another clinically obtained tumor source. Researchers carefully process and prepare the tissue before implantation.

The tumor fragment is then introduced into an appropriate immunodeficient animal.

Step 1: Patient Tumor Collection

The process begins with obtaining tumor tissue from a patient. Ethical approval, informed consent, sample handling procedures, and appropriate research protocols are essential.

The quality and quantity of the tumor sample can influence the success of PDX establishment.

Step 2: Tumor Implantation

The tumor tissue is implanted into an immunodeficient mouse.

Researchers may use different implantation approaches depending on the cancer type and research objective.

Step 3: Tumor Establishment

After implantation, researchers monitor the animal and tumor growth.

If the tumor successfully establishes, it can be expanded and characterized.

Step 4: Tumor Expansion

Established PDX tumors can be transferred into additional immunodeficient animals to generate larger experimental cohorts.

This process can provide researchers with multiple models derived from the original patient tumor.

Step 5: Molecular and Histological Characterization

Researchers can compare the PDX tumor with the original patient tumor using methods such as:

• Histopathology
• Immunohistochemistry
• DNA sequencing
• RNA sequencing
• Copy-number analysis
• Proteomic analysis
• Biomarker profiling

These analyses help determine how closely the model represents the original tumor.

Preserving Tumor Heterogeneity

Tumor heterogeneity is one of the most important challenges in cancer treatment.

A tumor may contain multiple cellular populations with different genetic and molecular characteristics. Some cells may be highly sensitive to therapy, while others may possess characteristics that allow them to survive treatment.

Traditional cancer cell lines may undergo significant changes after prolonged laboratory culture. As a result, they may not completely represent the complexity of the original patient tumor.

PDX models can preserve several aspects of tumor heterogeneity during early passages.

This makes them useful for studying how different tumor populations contribute to disease progression and therapeutic resistance.

However, PDX models are not perfect replicas of human tumors. During serial transplantation, certain tumor populations may become preferentially selected, resulting in evolutionary changes within the model.

Therefore, researchers must carefully characterize PDX models and monitor their molecular stability.

PDX Models and Precision Oncology

Precision oncology aims to move beyond a one-size-fits-all approach to cancer treatment.

Instead of selecting therapy solely according to tumor location or histological classification, precision oncology considers the molecular characteristics of an individual tumor.

Genomic testing can identify mutations, amplifications, deletions, fusions, and other molecular alterations that may influence treatment response.

PDX models can complement this information by providing a functional system for evaluating how a tumor actually responds to different therapeutic strategies.

For example, a patient's tumor may contain a potentially actionable molecular alteration. Researchers can establish a PDX model from that tumor and evaluate candidate therapies experimentally.

This creates an opportunity to connect:

Patient Tumor → Molecular Profile → Experimental Model → Drug Response → Precision Treatment Research

This combination of molecular information and functional testing represents an important direction for personalized cancer research.

PDX Models for Drug Development

Drug development is a lengthy and complex process.

Before a potential anticancer therapy can enter clinical testing, researchers need evidence regarding its biological activity, safety, pharmacology, and potential therapeutic value.

PDX models can contribute to the preclinical evaluation of candidate drugs.

Researchers may compare tumor growth in treated and untreated experimental groups and investigate whether a therapy produces tumor regression, growth inhibition, or resistance.

PDX models can also be used to investigate dose schedules and treatment combinations in appropriate research settings.

By testing candidate therapies against tumors derived from different patients, researchers may identify patterns of sensitivity and resistance that could inform subsequent clinical research.

Understanding Drug Resistance

Cancer treatment resistance remains one of the most significant barriers to successful cancer therapy.

A tumor may initially respond to treatment but later progress because resistant cancer cell populations survive and expand.

PDX models can help researchers investigate these mechanisms.

Researchers may establish models from treatment-naïve tumors and compare them with models derived from tumors that have progressed following treatment.

Molecular comparison can reveal changes associated with resistance.

Potential mechanisms may include:

• Secondary genetic alterations
• Activation of alternative signaling pathways
• Changes in tumor-cell states
• Alterations in drug metabolism
• Changes in DNA repair mechanisms
• Adaptation to therapeutic pressure
• Selection of resistant tumor populations

Understanding these mechanisms may help researchers develop strategies to overcome resistance.

PDX Models and Combination Therapies

Cancer treatment increasingly involves combination strategies.

Combining therapies can potentially target different biological pathways simultaneously and reduce the likelihood that resistant tumor populations will survive.

However, not every combination produces beneficial results.

PDX models can provide an experimental platform for evaluating combinations before they progress into more advanced research.

Researchers may investigate combinations involving:

• Targeted therapies
• Chemotherapy
• Hormonal therapies
• DNA-damage response inhibitors
• Kinase inhibitors
• Antiangiogenic agents
• Other emerging therapeutic approaches

The objective is not simply to identify whether a combination works, but also to understand which tumor characteristics are associated with response.

Integrating PDX Models With Genomics

Modern cancer research increasingly relies on large-scale genomic technologies.

Next-generation sequencing can identify genetic alterations within tumor samples.

When genomic profiling is combined with PDX modeling, researchers can examine the relationship between genotype and therapeutic response.

This approach can help answer important questions:

• Which mutations are associated with drug sensitivity?
• Which alterations contribute to resistance?
• Do genetically similar tumors respond similarly?
• Which molecular features may serve as predictive biomarkers?
• Can treatment response be predicted from tumor characteristics?

The integration of PDX models with genomic data therefore represents an important component of translational precision oncology.

PDX and Multi-Omics Research

Genomics provides only one layer of biological information.

Cancer research increasingly incorporates multiple molecular layers, including:

• Genomics
• Transcriptomics
• Proteomics
• Epigenomics
• Metabolomics

Combining these technologies with PDX models can provide a more comprehensive understanding of tumor biology.

For example, a genomic alteration may affect gene expression, which can subsequently influence protein signaling and cellular metabolism.

Multi-omics analysis can help researchers understand these interconnected processes.

This may lead to the identification of new biomarkers and therapeutic targets that would not be apparent from genomic analysis alone.

PDX Models and Biomarker Discovery

Biomarkers can provide valuable information about disease characteristics and treatment response.

A predictive biomarker may help identify patients who are more likely to benefit from a particular therapy.

PDX models can support biomarker research by allowing investigators to compare molecular characteristics between treatment-responsive and treatment-resistant tumors.

Researchers can then investigate whether particular genetic, transcriptomic, proteomic, or metabolic features correlate with therapeutic outcomes.

This approach may contribute to the development of more precise patient-selection strategies for clinical trials.

PDX Models in Cancer Types

PDX models have been developed for numerous malignancies.

Breast Cancer

Breast cancer PDX models can be used to study tumor heterogeneity, hormone receptor biology, targeted therapies, and treatment resistance.

Colorectal Cancer

Colorectal cancer PDX models are valuable for investigating molecular subtypes, targeted therapies, resistance mechanisms, and combination treatment strategies.

Lung Cancer

Lung cancer PDX models can support research into molecular alterations, targeted therapies, resistance, and emerging treatment approaches.

Pancreatic Cancer

Pancreatic cancer presents major challenges because of its complex biology and therapeutic resistance. PDX models can help researchers study tumor behavior and investigate potential therapies.

Ovarian Cancer

Ovarian cancer PDX models can be used to investigate treatment response, recurrence, resistance, and new therapeutic approaches.

Melanoma

Melanoma models can support research into targeted therapies and mechanisms of resistance associated with molecularly driven disease.

The suitability and characteristics of PDX models can vary considerably between tumor types and individual samples.

PDX Models and Metastatic Cancer

Metastatic cancer is particularly challenging because cancer cells can spread to different organs and develop distinct biological characteristics.

Primary and metastatic tumors from the same patient may not always behave identically.

PDX models derived from metastatic lesions can provide opportunities to study these differences.

Researchers can investigate how tumor cells adapt to different microenvironments and how metastatic tumors respond to therapy.

This may improve understanding of cancer progression and treatment resistance.

Advantages of Patient-Derived Xenografts

PDX models offer several potential advantages.

Clinically Relevant Tumor Material

Because PDX models originate from patient tumors, they can provide a more clinically relevant research system than some conventional laboratory models.

Preservation of Tumor Characteristics

Important histological and molecular characteristics may be maintained, particularly during early passages.

Drug Testing

PDX models can be used to evaluate candidate therapies and treatment combinations.

Heterogeneity Research

They can support investigations into tumor heterogeneity and treatment resistance.

Translational Research

PDX models can bridge laboratory research and clinical investigation.

Biomarker Discovery

They can help researchers identify molecular characteristics associated with treatment response.

Limitations of PDX Models

Despite their advantages, PDX models have important limitations.

One major limitation is the absence of a fully functional human immune system in conventional immunodeficient mouse models.

This is particularly important for cancer immunotherapy research because immune cells and immune signaling are fundamental components of tumor biology.

Another challenge is that the tumor microenvironment can change after transplantation.

Human stromal cells may gradually be replaced by mouse-derived stromal components.

Furthermore, serial transplantation can create selective pressures that alter tumor composition.

Other challenges include:

• Cost
• Time required for model establishment
• Variable engraftment rates
• Animal-related limitations
• Lack of complete human immune interactions
• Changes in tumor microenvironment
• Potential clonal selection
• Limited representation of the original patient population

Therefore, PDX models should be considered one component of a broader research strategy rather than a perfect representation of human cancer.

Humanized PDX Models

To overcome some limitations associated with conventional PDX systems, researchers are developing humanized PDX models.

These models attempt to introduce components of the human immune system into the experimental environment.

Humanized PDX systems may provide improved opportunities for studying:

• Cancer immunotherapy
• Tumor-immune interactions
• Immune checkpoint pathways
• Cellular therapies
• Immune-mediated treatment resistance

Although these models remain technically challenging, they represent an important area of research.

PDX Models and Immunotherapy Research

Immunotherapy has transformed cancer treatment, but response varies significantly between patients.

Understanding why some tumors respond to immune checkpoint inhibitors or other immunotherapies while others do not remains an important research goal.

Conventional PDX models are limited for this purpose because they generally lack a fully functional human immune system.

However, humanized models and other advanced experimental systems may help address this limitation.

Combining tumor genomics, immune profiling, and functional models could contribute to a deeper understanding of immunotherapy response.

PDX and Organoid Technologies

Cancer organoids have also emerged as valuable models for personalized cancer research.

Organoids are three-dimensional cellular structures grown under laboratory conditions and can reproduce certain characteristics of tumors.

PDX models and organoids offer complementary advantages.

Organoids can enable relatively rapid and scalable drug screening, while PDX models can provide a more complex in vivo environment.

Researchers are increasingly exploring ways to integrate these platforms.

A potential workflow could involve:

Patient Tumor → Organoid Model → PDX Model → Molecular Profiling → Drug Screening → Treatment Research

Such integrated approaches may improve the efficiency of precision oncology research.

The Future of PDX Models in Precision Cancer Care

The future of PDX research will likely involve greater integration with advanced technologies.

Artificial intelligence and machine learning may help researchers analyze large datasets generated from PDX experiments.

Digital pathology can provide detailed analysis of tumor architecture and cellular features.

Single-cell sequencing can help characterize individual tumor cell populations.

Spatial technologies can reveal how cells are organized within tumor tissues.

Multi-omics can connect genetic, molecular, and metabolic information.

Together, these technologies may transform PDX models from relatively traditional experimental systems into highly data-rich platforms for precision oncology.

PDX Models and Artificial Intelligence

Artificial intelligence may become increasingly important in PDX research.

Large datasets generated through genomic sequencing, imaging, pathology, and drug-response experiments can be difficult to analyze manually.

AI-based approaches may help identify patterns that are not immediately apparent.

Potential applications include:

• Predicting drug response
• Identifying resistance-associated biomarkers
• Classifying tumor phenotypes
• Analyzing histopathological images
• Integrating multi-omics datasets
• Modeling treatment outcomes

The combination of AI and PDX research could support more sophisticated approaches to cancer modeling and therapeutic discovery.

Moving Toward Patient-Specific Treatment Research

The ultimate goal of precision oncology is to provide the right treatment to the right patient at the right time.

PDX models contribute to this vision by allowing researchers to study tumors derived from individual patients.

However, PDX models are not currently a universal clinical decision-making tool. Their development can require significant time, resources, and specialized infrastructure.

For this reason, their strongest current contribution remains in translational research, drug development, biomarker discovery, and investigation of treatment mechanisms.

As technologies become faster and more scalable, their potential role in personalized cancer research may continue to expand.

Ethical Considerations in PDX Research

PDX research involves both human biological samples and laboratory animals.

Therefore, ethical considerations are essential.

Patient tumor samples must be collected under appropriate ethical frameworks, with informed consent and appropriate protection of patient information.

Animal experiments must follow institutional and regulatory requirements designed to promote responsible research and animal welfare.

Researchers must balance scientific objectives with ethical responsibilities throughout the PDX development and experimental process.

PDX Models: From Patient Tumor to Translational Discovery

The major strength of PDX technology lies in its ability to connect patient-derived biological material with experimental research.

A simplified translational pathway can be represented as:

Patient Tumor → PDX Establishment → Molecular Characterization → Therapeutic Testing → Biomarker Discovery → Translational Research

This framework can help researchers investigate cancer from multiple perspectives.

It also demonstrates how precision oncology increasingly depends on the integration of clinical samples, advanced laboratory models, molecular technologies, and computational analysis.

Conclusion

Patient-Derived Xenografts have become an important component of modern oncology research, offering researchers a valuable experimental platform for studying human tumors in vivo.

By preserving several characteristics of patient-derived tumors, PDX models can support investigations into tumor biology, therapeutic response, drug resistance, biomarker discovery, and precision drug development.

Their integration with genomics, transcriptomics, proteomics, artificial intelligence, digital pathology, organoid technology, and other advanced approaches is creating increasingly sophisticated cancer research models.

At the same time, important limitations remain, particularly regarding tumor microenvironment changes, immune-system representation, model establishment time, cost, and evolutionary changes during serial transplantation.

The future of PDX research will therefore depend on combining these models with complementary technologies rather than relying on PDX systems alone.

As oncology moves toward increasingly personalized and data-driven cancer care, PDX models can play an important role in translating discoveries from the laboratory toward clinically relevant research.

The continued development of patient-derived models, humanized systems, multi-omics technologies, computational approaches, and functional drug testing may ultimately strengthen the connection between individual tumor biology and precision cancer treatment.

The World Conference on Oncology & Cancer Care (WCOCC-2026) provides an international platform for researchers, clinicians, oncologists, healthcare professionals, and industry experts to exchange knowledge on emerging developments in oncology and cancer care, including precision medicine, cancer research, innovative therapeutics, and advanced technologies shaping the future of cancer treatment.

Frequently Asked Questions (FAQs)

1. What are Patient-Derived Xenografts (PDX)?

Patient-Derived Xenografts (PDX) are cancer research models created by implanting tumor tissue obtained from a patient into an immunodeficient animal, commonly a mouse. They are used to study tumor biology, treatment response, drug resistance, and cancer therapies.

2. Why are PDX models important in oncology research?

PDX models can preserve several biological and molecular characteristics of patient tumors, making them valuable for translational cancer research, therapeutic evaluation, biomarker discovery, and precision oncology.

3. How are PDX models used in precision oncology?

PDX models can be combined with genomic and molecular profiling to investigate how individual tumors respond to specific treatments. This can help researchers study patient-specific therapeutic responses and resistance mechanisms.

4. Can PDX models be used for cancer drug development?

Yes. PDX models can be used in preclinical research to evaluate candidate anticancer drugs, investigate treatment combinations, study drug sensitivity, and explore mechanisms of therapeutic resistance.

5. What are the main advantages of PDX models?

Key advantages include the use of patient-derived tumor tissue, preservation of important tumor characteristics, investigation of tumor heterogeneity, evaluation of therapeutic response, and support for translational cancer research.

6. What are the limitations of PDX models?

Important limitations include high cost, time required for model establishment, variable tumor engraftment, changes in the tumor microenvironment, potential clonal selection, and the lack of a fully functional human immune system in conventional PDX models.

7. How are PDX models combined with genomic technologies?

Researchers can perform genomic sequencing and molecular profiling of patient tumors and corresponding PDX models to investigate mutations, biomarkers, treatment response, and mechanisms of resistance.

8. What is the role of PDX models in cancer drug resistance research?

PDX models can help researchers compare treatment-sensitive and treatment-resistant tumors and investigate molecular mechanisms that allow cancer cells to survive therapeutic pressure.

9. What is the future of PDX research in oncology?

The future of PDX research is expected to involve greater integration with artificial intelligence, multi-omics, organoids, single-cell sequencing, digital pathology, and humanized models to improve precision cancer research and therapeutic development.

10. How does PDX research contribute to precision cancer care?

PDX research can help connect individual patient tumor characteristics with experimental treatment response, supporting the development of more personalized approaches to cancer research and precision drug development.